Genomics specialist Alka Chaubey has been appointed as the first chief medical and genomics officer at Nabsys 2.0, LLC, taking over the newly created position on July 6.
The appointment puts the veteran Indian American scientist into the top medical tier of the company as it scales up its proprietary electronic genome mapping platform.
Chaubey, who previously served as the chief medical officer at Bionano Genomics, brings more than 20 years of experience in molecular genetics, cytogenomics, and molecular diagnostics.
At Nabsys, based in Providence, Rhode Island, she will direct the company’s medical and scientific affairs strategy, focusing on expanding the adoption of its OhmX electronic genome mapping system. The technology maps structural variations in human DNA, which are important for analyzing cancer, constitutional conditions, and cell and gene therapies.
Read: Indian American researcher gets $4M NIH grant to study autoimmune disease (July 8, 2026)
Chaubey’s scientific background began in India, where she completed her advanced scientific education. After earning a Master of Science degree in life sciences, she did her PhD in biochemistry and molecular biology at Guru Nanak Dev University, Amritsar, Punjab.
Following her academic training, Chaubey built a career in the United States spanning laboratory leadership, corporate executiveship, and academic research.
She currently holds appointments as the scientific director of the Georgia Esoteric and Molecular Laboratory, the scientific director of the cytogenetics laboratory at Augusta University, and an adjunct assistant professor of pathology at the Medical College of Georgia at Augusta University.
Read: Ajay Thomas chosen chair-elect of Southwestern University board
(July 7, 2026)
A double board-certified specialist, Chaubey is certified in both clinical cytogenetics and genomics, as well as clinical molecular genetics and genomics, by the American Board of Medical Genetics and Genomics.
Her previous career includes serving as the head of cytogenomics at PerkinElmer Genomics and as the director of the cytogenomics laboratory at the Greenwood Genetic Center. She has authored and co-authored more than 100 scientific publications, abstracts, and book chapters.
Nabsys leadership stated that Chaubey’s experience with assay development and regulatory compliance under Clinical Laboratory Improvement Amendments and College of American Pathologists environments will guide the company’s next phase.
Backed by a global partnership with Hitachi High-Tech, Nabsys aims to transform its mapping technology into widely accessible, clinically validated workflows for researchers globally.